Carlos Fernandez-Pereira
Research Subjects
Carlos Fernandez-Pereira has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo E. Rodriguez
Division of Cardiology, Otamendi Hospital, Buenos Aires 1001, Argentina
6 shared publications Juan Mieres
Cardiovascular Research Center, Otamendi Hospital , Buenos Aires, Argentina
3 shared publications- Alfredo Matías Rodríguez Granillo
Servicio de Cardiología Intervencionista, Sanatorio Otamendi, Buenos Aires, Argentina
2 shared publications Hernán Pavlovsky
2 shared publications- Juan Mieres
Servicio de Cardiología Intervencionista, Sanatorio Las lomas, Buenos Aires, Argentina
2 shared publications - Adnan Kastrati
Deutsches Herzzentrum München
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1685
Systemic Use of Oral Rapamycin, Prednisone and Colchicine After Coronary Bare-Metal Stent Implantation: Narrative Review of Randomized Clinical Trials
Background: Coronary stenting remains the cornerstone of interventional cardiology. Drug-eluting stents (DES) have reduced restenosis compared to bare-metal stents (BMS), but their high cost and need for prolonged dual antiplatelet therapy (DAPT) limit accessibility in many regions. Recent evidence has revisited the potential role of systemic pharmacologic adjuncts—oral sirolimus (rapamycin), prednisone and colchicine—as cost-effective therapies to mitigate restenosis and adverse events following BMS implantation. Objective: This review critically evaluates the clinical and mechanistic evidence supporting the use of oral immunosuppressive or anti-inflammatory drugs following BMS implantation, with emphasis on their applicability in both resource-limited and general cardiology settings. Three randomized clinical trials comparing this strategy against DES are analyzed and discussed in this review. Conclusions: Oral sirolimus, prednisone, and colchicine demonstrate promising anti-inflammatory and antiproliferative effects that translate into clinical outcomes comparable to DES in a highly select population. Their systemic administration following BMS implantation may provide a feasible, cost-effective alternative where DES use is restricted by cost or clinical contraindications. Larger-scale, long-term trials are warranted to confirm safety, optimize dosing, and identify ideal patient populations for this “pharmacologic stent hybrid” strategy.
- 27 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1685
Open AccessSystemic Use of Oral Rapamycin, Prednisone and Colchicine After Coronary Bare-Metal Stent Implantation: Narrative Review of Randomized Clinical Trials
Background: Coronary stenting remains the cornerstone of interventional cardiology. Drug-eluting stents (DES) have reduced restenosis compared to bare-metal stents (BMS), but their high cost and need for prolonged dual antiplatelet therapy (DAPT) limit accessibility in many regions. Recent evidence has revisited the potential role of systemic pharmacologic adjuncts—oral sirolimus (rapamycin), prednisone and colchicine—as cost-effective therapies to mitigate restenosis and adverse events following BMS implantation. Objective: This review critically evaluates the clinical and mechanistic evidence supporting the use of oral immunosuppressive or anti-inflammatory drugs following BMS implantation, with emphasis on their applicability in both resource-limited and general cardiology settings. Three randomized clinical trials comparing this strategy against DES are analyzed and discussed in this review. Conclusions: Oral sirolimus, prednisone, and colchicine demonstrate promising anti-inflammatory and antiproliferative effects that translate into clinical outcomes comparable to DES in a highly select population. Their systemic administration following BMS implantation may provide a feasible, cost-effective alternative where DES use is restricted by cost or clinical contraindications. Larger-scale, long-term trials are warranted to confirm safety, optimize dosing, and identify ideal patient populations for this “pharmacologic stent hybrid” strategy.
- Open Access
- 22 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 2871
Randomized Clinical Trial Comparing Bare-Metal Stents Plus Colchicine Versus Drug-Eluting Stents for Preventing Adverse Cardiac Outcomes: Three-Year Follow-Up Results of the ORal Colchicine in Argentina (ORCA) Trial
Background: In patients with coronary artery disease, bare-metal stents (BMS) are considered a safer but less effective treatment than drug-eluting stents (DES). Oral colchicine therapy may compensate for this limitation of BMS. This randomized trial compared the cost-effectiveness of two different revascularization strategies during percutaneous coronary intervention (PCI). Methods: Between March 2020 and April 2022, 410 patients were randomly treated with PCI with BMS plus colchicine (BMS-CO: 205 patients) or DES (205 patients) The patients in the BMS-CO group received 0.5 mg oral doses of colchicine for 3 months. The primary endpoint was major adverse cardiac and cerebrovascular events (MACEs), defined as the composite of death, myocardial infarction, stroke, or target vessel revascularization (TVR), and the costs of each treatment strategy. The secondary endpoints included the individual components of MACEs. Results: No significant differences were observed in baseline characteristics, and 76% of the patients presented with acute coronary syndromes. The median follow-up period was 36.8 months. Five percent of the patients in the BMS-CO group discontinued study medication. The cumulative incidence of MACEs was not significantly different, with 12.7% in the BMS-CO group and 15.6% in the DES2G group (p = 0.39) as well individual components of the clinical endpoint. The cumulative costs were lower in the BMS-CO group than in the DES2G group (USD 4826.4 ± 2512 vs. USD 5708 ± 3637, p < 0.001). Conclusions: In the 3 years, the DES strategy failed to be cost-saving compared to BMS-CO. However, due to the small sample size, the equivalence in clinical outcomes with both strategies can occur by chance (NCT04382443).
- 22 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 2871
Open AccessRandomized Clinical Trial Comparing Bare-Metal Stents Plus Colchicine Versus Drug-Eluting Stents for Preventing Adverse Cardiac Outcomes: Three-Year Follow-Up Results of the ORal Colchicine in Argentina (ORCA) Trial
Background: In patients with coronary artery disease, bare-metal stents (BMS) are considered a safer but less effective treatment than drug-eluting stents (DES). Oral colchicine therapy may compensate for this limitation of BMS. This randomized trial compared the cost-effectiveness of two different revascularization strategies during percutaneous coronary intervention (PCI). Methods: Between March 2020 and April 2022, 410 patients were randomly treated with PCI with BMS plus colchicine (BMS-CO: 205 patients) or DES (205 patients) The patients in the BMS-CO group received 0.5 mg oral doses of colchicine for 3 months. The primary endpoint was major adverse cardiac and cerebrovascular events (MACEs), defined as the composite of death, myocardial infarction, stroke, or target vessel revascularization (TVR), and the costs of each treatment strategy. The secondary endpoints included the individual components of MACEs. Results: No significant differences were observed in baseline characteristics, and 76% of the patients presented with acute coronary syndromes. The median follow-up period was 36.8 months. Five percent of the patients in the BMS-CO group discontinued study medication. The cumulative incidence of MACEs was not significantly different, with 12.7% in the BMS-CO group and 15.6% in the DES2G group (p = 0.39) as well individual components of the clinical endpoint. The cumulative costs were lower in the BMS-CO group than in the DES2G group (USD 4826.4 ± 2512 vs. USD 5708 ± 3637, p < 0.001). Conclusions: In the 3 years, the DES strategy failed to be cost-saving compared to BMS-CO. However, due to the small sample size, the equivalence in clinical outcomes with both strategies can occur by chance (NCT04382443).
- 12 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (11) , 894-895
Letter by Rodriguez et al Regarding Article, “Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial”
- 12 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (11) , 894-895
Letter by Rodriguez et al Regarding Article, “Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial”
- Open Access
- 2 April 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (7) , 1321
High Non-Cardiac Death Incidence Should Be a Limitation of Drug-Eluting Stents Implantation? Insights from Recent Randomized Data
Despite the introduction of drug-eluting stents (DES) significantly improved the efficacy and safety of percutaneous coronary interventions (PCI), particularly in a high-risk group of patients, the gap between PCI with his competitor’s coronary artery bypass surgery (CABG) and/or optimal medical treatment alone was not reduced. In this revision, we highlighted the fact that in recent years landmark randomized studies reported at mid and long-term follow-ups a high incidence of non-cardiac death, cancer incidence, or both in the DES group of patients. The overall incidence of non-cardiac death was significantly higher in the DES vs. the comparator arm: 5.5% and 3.8%, respectively, p = 0.000018, and non-cardiac death appears to be more divergent between DES vs. the comparator at the extended follow-up to expenses of the last one. One of these trials reported five times greater cancer incidence in the DES arm at late follow-up, 5% vs. 0.7% p < 0.0018. We review the potential reason for these unexpected findings, although we can discard that DES biology could be involved in it. Until all these issues are resolved, we propose that DES implantation should be tailored accorded patient age, life expectancy, and lesion complexity.
- 2 April 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (7) , 1321
Open AccessHigh Non-Cardiac Death Incidence Should Be a Limitation of Drug-Eluting Stents Implantation? Insights from Recent Randomized Data
Despite the introduction of drug-eluting stents (DES) significantly improved the efficacy and safety of percutaneous coronary interventions (PCI), particularly in a high-risk group of patients, the gap between PCI with his competitor’s coronary artery bypass surgery (CABG) and/or optimal medical treatment alone was not reduced. In this revision, we highlighted the fact that in recent years landmark randomized studies reported at mid and long-term follow-ups a high incidence of non-cardiac death, cancer incidence, or both in the DES group of patients. The overall incidence of non-cardiac death was significantly higher in the DES vs. the comparator arm: 5.5% and 3.8%, respectively, p = 0.000018, and non-cardiac death appears to be more divergent between DES vs. the comparator at the extended follow-up to expenses of the last one. One of these trials reported five times greater cancer incidence in the DES arm at late follow-up, 5% vs. 0.7% p < 0.0018. We review the potential reason for these unexpected findings, although we can discard that DES biology could be involved in it. Until all these issues are resolved, we propose that DES implantation should be tailored accorded patient age, life expectancy, and lesion complexity.
- Open Access
- 25 February 2022
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 2 (2) , oeac012
Is non-cardiac death increased with an initial invasive revascularization strategy? Commentary on the ISCHEMIA trial
In a recent issue of partner journal from the ESC Journals family, the incidence of cardiovascular adverse events at 4 years of follow-up in the ISCHEMIA trial was reported. 1 In such manuscript, authors did not find any significant differences between initial Invasive (INV) or Conservative (CON) strategies in the number of composite or individual cardiac events.
- 25 February 2022
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 2 (2) , oeac012
Open AccessIs non-cardiac death increased with an initial invasive revascularization strategy? Commentary on the ISCHEMIA trial
In a recent issue of partner journal from the ESC Journals family, the incidence of cardiovascular adverse events at 4 years of follow-up in the ISCHEMIA trial was reported. 1 In such manuscript, authors did not find any significant differences between initial Invasive (INV) or Conservative (CON) strategies in the number of composite or individual cardiac events.
- Open Access
- 30 December 2019
- Published by Publicaciones Latinoamericanas SRL in Revista Argentina de Cardioangiología Intervencionista
- Vol. 10 (04)
Manejo perioperatorio de la terapia antiplaquetaria dual en pacientes con implante reciente de stent coronario que requieren cirugía. Terapia puente
- 30 December 2019
- Published by Publicaciones Latinoamericanas SRL in Revista Argentina de Cardioangiología Intervencionista
- Vol. 10 (04)
Open AccessManejo perioperatorio de la terapia antiplaquetaria dual en pacientes con implante reciente de stent coronario que requieren cirugía. Terapia puente
- Open Access
- 1 January 2019
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 13
One-Year Follow-Up Results From the Observational, Multicenter, Prospective, and Controlled Registry: The WALTZ All-Comers Study
The aim of this study was to evaluate 1-year follow-up results in an all “comers” population treated with a new cobalt chromium bare-metal stent (BMS) design. Since August 2016 to March 2017, 201 (9.7% of screening population) consecutive patients undergoing coronary stent implantation in 11 centers in Argentina were prospectively included in our registry. The inclusion criteria were multiple-vessel disease and/or unprotected left main disease, acute coronary syndromes (ACS) with at least one severe (⩾70%) stenosis in any of major epicardial vessel. In-stent restenosis, protected left main stenosis, or impossibility to receive dual-antiplatelet therapy was an exclusion criterion. Major adverse cardiac events (MACE) were the primary endpoint and included cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR); also, all components of the primary endpoint were separately analyzed. Completeness of revascularization was analyzed as post hoc data using residual SYNTAX or ERACI risk scores. Demographic characteristics showed that 6.5% of patients were very elderly, 22.5% have diabetes, 47% have multiple-vessel disease, 67% have ACS, and 32% have ST elevation MI. At a mean of 376 ± 18.1 days of follow-up, MACE was observed in 10.4% of patients: death + MI + cardiovascular accident (CVA) in 3% (6 of 201) and cardiac death + MI + CVA in 1.5% (3 of 201). Residual ERACI score ⩽5 was associated with 98% of event-free survival (P < .04). In conclusion, this prospective, multicenter, and observational all-comers registry with this novel BMS design showed a low incidence of adverse events at 1 year mainly due to coronary restenosis.
- 1 January 2019
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 13
Open AccessOne-Year Follow-Up Results From the Observational, Multicenter, Prospective, and Controlled Registry: The WALTZ All-Comers Study
The aim of this study was to evaluate 1-year follow-up results in an all “comers” population treated with a new cobalt chromium bare-metal stent (BMS) design. Since August 2016 to March 2017, 201 (9.7% of screening population) consecutive patients undergoing coronary stent implantation in 11 centers in Argentina were prospectively included in our registry. The inclusion criteria were multiple-vessel disease and/or unprotected left main disease, acute coronary syndromes (ACS) with at least one severe (⩾70%) stenosis in any of major epicardial vessel. In-stent restenosis, protected left main stenosis, or impossibility to receive dual-antiplatelet therapy was an exclusion criterion. Major adverse cardiac events (MACE) were the primary endpoint and included cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR); also, all components of the primary endpoint were separately analyzed. Completeness of revascularization was analyzed as post hoc data using residual SYNTAX or ERACI risk scores. Demographic characteristics showed that 6.5% of patients were very elderly, 22.5% have diabetes, 47% have multiple-vessel disease, 67% have ACS, and 32% have ST elevation MI. At a mean of 376 ± 18.1 days of follow-up, MACE was observed in 10.4% of patients: death + MI + cardiovascular accident (CVA) in 3% (6 of 201) and cardiac death + MI + CVA in 1.5% (3 of 201). Residual ERACI score ⩽5 was associated with 98% of event-free survival (P < .04). In conclusion, this prospective, multicenter, and observational all-comers registry with this novel BMS design showed a low incidence of adverse events at 1 year mainly due to coronary restenosis.
- Open Access
- 31 December 2018
- Published by Publicaciones Latinoamericanas SRL in Revista Argentina de Cardioangiología Intervencionista
- Vol. 09 (04)
Stent dedicado de bifurcación BiOSS LIM C® en reestenosis de bifurcación y trifurcación coronarias
- 31 December 2018
- Published by Publicaciones Latinoamericanas SRL in Revista Argentina de Cardioangiología Intervencionista
- Vol. 09 (04)
Open AccessStent dedicado de bifurcación BiOSS LIM C® en reestenosis de bifurcación y trifurcación coronarias